Patent US4835173A successfully refreshed from Google Patents.
US4835173A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of medical treatment
Assignee: Glaxo Group Ltd
•
Filing: 1987-12-16
•
Granted: 1989-05-30
•
Expires: 2007-12-16
Abstract
Abstract The invention relates to the use of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one and physiologically acceptable salts and solvates thereof in the treatment of depression.
Inventors
- 👤 Michael B. Tyers
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 19:56
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/41; A61K31/415; A61P; A61P25/00; A61P25/24; A61P25/26
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
48 words
A method for the treatment of depression in a human or animal subject suffering from or susceptible to depression, which comprises administering to the human or animal subject an effective amount for treatment of depression in said subject of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl-]4H-carbazol-4-one or a physiologically acceptable salt or solvate thereof.
Claim 2
Independent Claim
48 words
A method for the treatment of depression in a human or animal subject suffering from or susceptible to depression, which comprises administering to the human or animal subject an effective amount for treatment of depression in said subject of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl-]4H-carbazol-4-one or a physiologically acceptable salt or solvate thereof.
Claim 3
Dependent Claim
18 words
A method according to claim 1 wherein said 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one is administered in the form of a hydrochloride salt.
Claim 4
Dependent Claim
19 words
A method according to claim 1 wherein said 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one is administered in the form of the hydrochloride dihydrate salt.
Claim 5
Dependent Claim
44 words
A method according to claim 1 wherein said 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one or a physiologically acceptable salt or solvate thereof is administered in a dose of 0.05 to 20 mg from 1 to 4 times per day, the dose being expressed as the weight of free base.
Claim 6
Dependent Claim
22 words
A method according to claim 4 wherein said dose is from 0.1 to 10 mg from 1 to 4 times per day.
Claim 7
Dependent Claim
20 words
A method according to claim 1 wherein said 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one is administered orally, bucally, parenterally, rectally or as a depot preparation.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-05-29 | 1992-11-28 | 1993-05-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-05-29 | 1996-11-28 | 1997-05-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-05-29 | 2000-11-28 | 2001-05-30 | $7700.00 | Window Closed / Lapsed |